TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38824243

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control (no surgery)
Number of subjects: 357
Study: 38824244

Group type: EXPERIMENTAL
Intervention: Inhibition of KAT6A and KAT6B
Number of subjects: 0
Study: 38824432

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 3048

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 3048
Study: 38824442

Group type: EXPERIMENTAL
Intervention: Stepped palliative care (initial visit within 4 weeks, subsequent visits based on treatment changes or hospitalizations)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Early palliative care (visits every 4 weeks after enrollment)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Stepped palliative care
Number of subjects: 507

Group type: COMPARATOR
Intervention: Early palliative care
Number of subjects: 507
Study: 38824537

Group type: EXPERIMENTAL
Intervention: Simulation-based team training intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no simulation-based team training)
Number of subjects: 0
Study: 38824540

Group type: EXPERIMENTAL
Intervention: Equia Forte (EF)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Riva Self Cure (RSC)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 152
Study: 38824583

Group type: EXPERIMENTAL
Intervention: Rebamipide gargle
Number of subjects: 100

Group type: COMPARATOR
Intervention: Benzydamine gargle
Number of subjects: 100
Study: 38824626

Group type: EXPERIMENTAL
Intervention: Centanafadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lisdexamfetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viloxazine ER
Number of subjects: 0
Study: 38824658

Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: molecularly matched therapy
Number of subjects: 61
Study: 38824836

Group type: EXPERIMENTAL
Intervention: Antibiotic-cement coated plate
Number of subjects: 0

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 0
Study: 38824872

Group type: EXPERIMENTAL
Intervention: Arthro-distension with early and intensive mobilization (ADM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intra-articular steroid injection (ISI)
Number of subjects: 66
Study: 38824899

Group type: EXPERIMENTAL
Intervention: 12 weeks of telerehabilitation training (EG)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 182
Study: 38824918

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hydroxyurea PK dosing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hydroxyurea default dose
Number of subjects: 100
Study: 38824941

Group type: EXPERIMENTAL
Intervention: sintilimab (200 mg intravenously once every 3 weeks for 12 cycles)
Number of subjects: 425

Group type: COMPARATOR
Intervention: standard therapy (gemcitabine and cisplatin induction chemotherapy followed by concurrent cisplatin radiotherapy)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: sintilimab
Number of subjects: 425

Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 425
Study: 38824959

Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA (dd-cfDNA)
Number of subjects: 2882

Group type: COMPARATOR
Intervention: Inclusion of dd-cfDNA to standard of care prediction model
Number of subjects: 2882
Study: 38825005

Group type: EXPERIMENTAL
Intervention: Papaverine (80 mg intravenous)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline solution)
Number of subjects: 110
Study: 38825014

Group type: EXPERIMENTAL
Intervention: High energy density food (>3.0 kcal/g)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Medium energy density food (1.7-2.0 kcal/g)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low energy density food (∼1.0 kcal/g)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Later energy intake (post-meal energy intake)
Number of subjects: 66
Study: 38825182

Group type: EXPERIMENTAL
Intervention: Machine learning models based on physical examination (Classic Model)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Machine learning models based on ultrasound measurements
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Univariate analysis of predictor variables
Number of subjects: 400
Study: 38825184

Group type: EXPERIMENTAL
Intervention: PortionSize
Number of subjects: 43

Group type: COMPARATOR
Intervention: MyFitnessPal (MFP)
Number of subjects: 43
Study: 38825333

Group type: EXPERIMENTAL
Intervention: Specialised mood disorder clinic treatment combining evidence-based pharmacological treatment with group psychoeducation
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Specialised mood disorder clinic treatment
Number of subjects: 158
Study: 38825359

Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 38825603

Group type: EXPERIMENTAL
Intervention: Robotic insertion (RobOtol, Colin, France)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional insertion
Number of subjects: 37
Study: 38825627

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg
Number of subjects: 524

Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1) 3.6 mg/kg
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events for T-DXd
Number of subjects: 524

Group type: COMPARATOR
Intervention: Treatment-emergent adverse events for T-DM1
Number of subjects: 524
Study: 38825628

Group type: EXPERIMENTAL
Intervention: Prognostic Stage (PS)
Number of subjects: 6924

Group type: COMPARATOR
Intervention: Anatomic Stage (AS)
Number of subjects: 6924
Study: 38825688

Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA), Balloon pulmonary angioplasty (BPA), and targeted medical therapy
Number of subjects: 1500
Study: 38825840

Group type: EXPERIMENTAL
Intervention: Automated atlas-based volumetry (44 regions)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Automated planimetric measures of brainstem regions
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Staging systems
Number of subjects: 508

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 508
Study: 38825999

Group type: EXPERIMENTAL
Intervention: Computer-based biodex balance exercise system (BBS) performed twice weekly for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group received information regarding diabetes self-management
Number of subjects: 32
Study: 38826207

Group type: EXPERIMENTAL
Intervention: Telemedicine support (Anesthesiology Control Tower - ACT)
Number of subjects: 71927

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71927

Group type: EXPERIMENTAL
Intervention: Telemedicine support (ACT)
Number of subjects: 71927
Study: 38826330

Group type: EXPERIMENTAL
Intervention: Seclidemstat (SP-2577)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SP-2509 (noncompetitive inhibitor)
Number of subjects: 0
Study: 38826341

Group type: EXPERIMENTAL
Intervention: Almond consumption for 8 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cracker consumption for 8 weeks
Number of subjects: 73
Study: 38826471

Group type: EXPERIMENTAL
Intervention: Assisted group (clinicians reviewed machine learning predictions)
Number of subjects: 5071

Group type: COMPARATOR
Intervention: Unassisted group (clinicians reviewed without machine learning predictions)
Number of subjects: 5071
Study: 38826570

Group type: EXPERIMENTAL
Intervention: Standard step-up conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination csDMARDs (methotrexate with either sulfasalazine or leflunomide)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early biologics induction therapy (adalimumab plus methotrexate)
Number of subjects: 100
Study: 38826616

Group type: EXPERIMENTAL
Intervention: Cortical grey matter volume in left superior frontal gyrus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Motor scores
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conners 3 ADHD Index scores
Number of subjects: 30
Study: 38826786

Group type: EXPERIMENTAL
Intervention: SPd-40 (selinexor 40 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SPd-60 (selinexor 60 mg)
Number of subjects: 48
Study: 38827219

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed cow's milk protein-based infant formula (pHF)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard intact cow's milk protein-based formula (IPF)
Number of subjects: 288
Study: 38827437

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 80
Study: 38827749

Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19) primary-series vaccination
Number of subjects: 2020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2020
Study: 38827798

Group type: EXPERIMENTAL
Intervention: Early urethral catheter removal after 24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed urethral catheter removal
Number of subjects: 0
Study: 38827854

Group type: EXPERIMENTAL
Intervention: Oral Hydroxychloroquine (HC), Azithromycin (AZ), and Oseltamivir (OS)
Number of subjects: 471
Study: 38827880

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Salbutamol + MgSO4 250mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Salbutamol + MgSO4 500mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Salbutamol + MgSO4 750mg
Number of subjects: 104
Study: 38828023

Group type: EXPERIMENTAL
Intervention: 25 mg HCTZ for four days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg henagliflozin for four days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25 mg HCTZ + 10 mg henagliflozin for four days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Combination therapy (HCTZ + henagliflozin)
Number of subjects: 12
Study: 38828109

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Weekly chloroquine prophylaxis (CQ)
Number of subjects: 660
Study: 38828482

Group type: EXPERIMENTAL
Intervention: Tuune decision aid
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control aid
Number of subjects: 310
Study: 38828522

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 396

Group type: COMPARATOR
Intervention: SMS
Number of subjects: 396

Group type: COMPARATOR
Intervention: Diary card
Number of subjects: 396
Study: 38828563

Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban regimen (60/30 mg daily)
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Lower dose edoxaban regimen (30/15 mg daily)
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study: 38828679

Group type: EXPERIMENTAL
Intervention: CVD risk estimation via a self-directed screening station implemented in 14 pathology service sites.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CVD risk estimation service integration into routine workflow at pathology services.
Number of subjects: 26
Study: 38828895

Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 38828933

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, bortezomib, and dexamethasone (BVd)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Daratumumab, bortezomib, and dexamethasone (DVd)
Number of subjects: 494
Study: 38828938

Group type: EXPERIMENTAL
Intervention: Once weekly paclitaxel
Number of subjects: 240

Group type: COMPARATOR
Intervention: Once every 3 weeks docetaxel
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High-risk genotype
Number of subjects: 240

Group type: COMPARATOR
Intervention: Low-risk genotype
Number of subjects: 240
Study: 38828945

Group type: EXPERIMENTAL
Intervention: Crinecerfont
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 38828946

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 38828951

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, pomalidomide, and dexamethasone (BPd)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Pomalidomide, bortezomib, and dexamethasone (PVd)
Number of subjects: 302
Study: 38828955

Group type: EXPERIMENTAL
Intervention: Crinecerfont
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 38828959

Group type: EXPERIMENTAL
Intervention: 80 mg osimertinib once daily
Number of subjects: 73
Study: 38828957

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 0
Study: 38828958

Group type: EXPERIMENTAL
Intervention: IV posaconazole 300 mg q12h and 300 mg q8h for the first two days, followed by 400 mg q24h maintenance
Number of subjects: 31

Group type: COMPARATOR
Intervention: IV posaconazole 300 mg q24h
Number of subjects: 31
Study: 38828984

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab plus nivolumab followed by surgery
Number of subjects: 423

Group type: COMPARATOR
Intervention: Surgery followed by 12 cycles of adjuvant nivolumab
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab plus nivolumab
Number of subjects: 423
Study: 38829011

Group type: EXPERIMENTAL
Intervention: Dual-IVT strategy with tenecteplase 0.25 mg/kg
Number of subjects: 294

Group type: COMPARATOR
Intervention: Single-IVT approach with alteplase
Number of subjects: 294
Study: 38829281

Group type: EXPERIMENTAL
Intervention: Automated analysis of thoraco-abdominal asynchrony using respiratory inductance plethysmography; parameters include phase angle, loop rotation, global phase delay, and loop area.
Number of subjects: 2290

Group type: EXPERIMENTAL
Intervention: Global phase delay as a parameter for diagnosis and follow-up of clinical conditions leading to TAA.
Number of subjects: 2290
Study: 38829396

Group type: EXPERIMENTAL
Intervention: Tele-counseling intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 38829416

Group type: EXPERIMENTAL
Intervention: RTXM83-CHOP
Number of subjects: 27

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 27
Study: 38829437

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study: 38829483

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Hyaluronic Acid (LMWHA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: High Molecular Weight Hyaluronic Acid (HMWHA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 36
Study: 38829506

Group type: EXPERIMENTAL
Intervention: Platinum-based neoadjuvant chemotherapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Anthracycline-based neoadjuvant chemotherapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Comparison of Platinum-based vs Anthracycline-based
Number of subjects: 210
Study: 38829609

Group type: EXPERIMENTAL
Intervention: HugeMed® videolaryngoscope (HVL)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (MDL)
Number of subjects: 88
Study: 38829616

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Duodenal switch (DS)
Number of subjects: 60
Study: 38829618

Group type: EXPERIMENTAL
Intervention: Remote monitoring of BP and medication adherence (RM)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Remote monitoring of BP and medication adherence with social support (SS)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 246
Study: 38829619

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 158
Study: 38829664

Group type: EXPERIMENTAL
Intervention: Gradual weaning protocol (n=176) with additional 6 months of nighttime wear before stopping
Number of subjects: 369

Group type: COMPARATOR
Intervention: Immediate weaning protocol (n=193) with immediate brace removal
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Gradual weaning protocol
Number of subjects: 369

Group type: COMPARATOR
Intervention: Immediate weaning protocol
Number of subjects: 369
Study: 38829692

Group type: EXPERIMENTAL
Intervention: Oncoplastic partial mastectomy
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Partial mastectomy
Number of subjects: 340

Group type: COMPARATOR
Intervention: Mastectomy with immediate reconstruction
Number of subjects: 340

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 340
Study: 38829703

Group type: EXPERIMENTAL
Intervention: Lademirsen, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 38829821

Group type: EXPERIMENTAL
Intervention: +P (PCV13)
Number of subjects: 261

Group type: COMPARATOR
Intervention: +S (PHiD-CV10)
Number of subjects: 261
Study: 38829880

Group type: EXPERIMENTAL
Intervention: Multicomponent quality improvement (QI) strategy
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1146
Study: 38829882

Group type: EXPERIMENTAL
Intervention: EPO-Feeding Program (four weekly group-based training sessions led by healthcare professionals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPO-Feeding Program
Number of subjects: 0
Study: 38829894

Group type: EXPERIMENTAL
Intervention: ALA plaster 1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ALA plaster 2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ALA plaster 1 and 2
Number of subjects: 16
Study: 38830030

Group type: EXPERIMENTAL
Intervention: 2 rounds of fecal immunochemical testing (FIT) 2 years apart
Number of subjects: 90537

Group type: COMPARATOR
Intervention: Primary colonoscopy
Number of subjects: 90537
Study: 38830188

Group type: EXPERIMENTAL
Intervention: Topography-guided femtosecond LASIK
Number of subjects: 30
Study: 38830189

Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 331

Group type: COMPARATOR
Intervention: ConDSAEK
Number of subjects: 331

Group type: COMPARATOR
Intervention: UT-DSAEK
Number of subjects: 331

Group type: COMPARATOR
Intervention: ConDSAEK and UT-DSAEK
Number of subjects: 331
Study: 38830303

Group type: EXPERIMENTAL
Intervention: platinum-pemetrexed-atezolizumab-bevacizumab (PPAB)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: platinum-pemetrexed-atezolizumab (PPA)
Number of subjects: 140
Study: 38830375

Group type: EXPERIMENTAL
Intervention: 90 μg VLA15
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: 135 μg VLA15
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: 180 μg VLA15
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study: 38830408

Group type: EXPERIMENTAL
Intervention: preg-MEDAS
Number of subjects: 812
Study: 38830472

Group type: EXPERIMENTAL
Intervention: Yogurt + honey with Bifidobacterium animalis subsp. lactis DN-173 010/CNCM I-2494
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no honey)
Number of subjects: 66
Study: 38830735

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered as 1 g at skin incision, followed by an additional 1 g prior to skin closure.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA).
Number of subjects: 0
Study: 38830741

Group type: EXPERIMENTAL
Intervention: WHOOP Arrhythmia Notification Feature (WARN) algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: BioTel ePatch (electrocardiography gold-standard)
Number of subjects: 0
Study: 38830744

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Number of subjects: 82

Group type: COMPARATOR
Intervention: Back school
Number of subjects: 82
Study: 38830745

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA) using dexmedetomidine and lidocaine
Number of subjects: 268

Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (OBA) using remifentanil
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (OBA)
Number of subjects: 268
Study: 38830904

Group type: EXPERIMENTAL
Intervention: Controlled Crohn's disease
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no evident pathogenic abnormality)
Number of subjects: 22
Study: 38830962

Group type: EXPERIMENTAL
Intervention: Phase 2 white kidney bean extract (WKBE HIGH) 1000 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Phase 2 white kidney bean extract (WKBE LOW) 700 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 81
Study: 38830991

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 130
Study: 38830992

Group type: EXPERIMENTAL
Intervention: satri-cel monotherapy in 61 patients with standard chemotherapy-refractory gastrointestinal cancers
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: satri-cel plus anti-PD-1 therapy in 15 patients with standard chemotherapy-refractory gastrointestinal cancers
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: satri-cel as sequential treatment after first-line therapy in five patients with gastrointestinal cancers
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: satri-cel monotherapy in two patients with anti-CLDN18.2 monoclonal antibody-refractory gastric cancer
Number of subjects: 98
Study: 38830994

Group type: EXPERIMENTAL
Intervention: Isatuximab, lenalidomide, and dexamethasone (IsaRd)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Isatuximab, lenalidomide, dexamethasone, and bortezomib (Isa-VRd)
Number of subjects: 270
Study: 38831029

Group type: EXPERIMENTAL
Intervention: Remimazolam-flumazenil
Number of subjects: 53

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 53
Study: 38831218

Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 80

Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 80
Study: 38831266

Group type: EXPERIMENTAL
Intervention: Peer group intervention implemented by trained community volunteers
Number of subjects: 771

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 771